Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease

Bibliography

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease. Jan 2009. Available from: http://www.goldcopd.com [Last accessed 16 June 2009]
   Google Scholar
• Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-24
   PubMed Web of Science ®Google Scholar
• Mallia P, Contoli M, Caramori G, et al. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. Curr Pharm Des 2007;13:73-97
   PubMed Web of Science ®Google Scholar
• The world health report 1998- life in the 21st century- a vision for all by the world health organization. World Health Organization. March 1998. Available from: http://ftp.who.int/gb/archive/pdf_files/WHA51/ea3.pdf [Last accessed 16 June 2009]
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Potter BVL. Comprehensive medicinal chemistry. Oxford (UK): Pergamon Press, 1990
   Google Scholar
• Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 2005;48:3449-62
   PubMed Web of Science ®Google Scholar
• Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005;25:229-44
   PubMed Web of Science ®Google Scholar
• Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-6
   PubMed Web of Science ®Google Scholar
• Draheim R, Egerland U, Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glycoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004;308:555-63
   PubMed Web of Science ®Google Scholar
• Jeffery P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm Pharmacol Ther 2005;18:9-17
   PubMed Web of Science ®Google Scholar
• O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25:158-63
   PubMed Web of Science ®Google Scholar
• Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 2004;3:231-6
   PubMedGoogle Scholar
• Mata M, Sarria B, Buenestado A, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-52
   PubMed Web of Science ®Google Scholar
• Jeon YH, Heo YS, Kim CM, et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005;62:1198-220
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-19
   PubMed Web of Science ®Google Scholar
• Dini FL, Cogo R. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr Med Res Opin 2001;16:258-68
   PubMed Web of Science ®Google Scholar
• Cruse G, Duffy SM, Brightling CE, Bradding P. Functional KCa 3.1 K+ channels are required for human lung mast cell migration. Thorax 2006;61:880-5
   PubMedGoogle Scholar
• Zhou B, Cai SX, Zou F, et al. Effect of doxofylline on calcium-activated potassium channels in human peripheral blood eosinophils in asthma. Zhonghua Jie He He Hu Xi Za Zhi 2005;28:817-9
   PubMedGoogle Scholar
• Sullivan P, Jaffar Z, Page C, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-8
   PubMed Web of Science ®Google Scholar
• Franzone JS, Cirillo R, Biffignandi P. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur J Pharmacol 1989;165:269-77
   PubMed Web of Science ®Google Scholar
• Franzone JS, Cirillo R, Barone D. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals. Drug Explt Clin Res 1988;14:479-89
   PubMedGoogle Scholar
• Franzone JS, Cirillo R, Reboani MC. Doxofylline differs from methylxanthines in its movement of cytosolic calcium. Int J Tissue React 1991;13:131-8
   PubMedGoogle Scholar
• Guo H, Xu XY, He LY, Huang JH. Preliminary study on the absorption, distribution and excretion of doxophylline in rats. Yao Xue Xue Bao 1997;32:81-4
   PubMedGoogle Scholar
• Bologna E, Lagana A, Terracino D, et al. Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. J Int Med Res 1990;18:282-8
   PubMedGoogle Scholar
• Jian G, Chunyan Z, Zhaolong C, et al. The pharmacokinetics of doxofylline in Chinese. Chin J New Drugs 2000;6:396-8
   Google Scholar
• Gannu R, Bandari S, Sudke SG, et al. Development and validation of a stability-indicating RP-HPLC method for analysis of doxofylline in human serum. Application of the method to a pharmacokinetic study. Acta Chromatographica 2007;19:149-60
   Web of Science ®Google Scholar
• Lee JH, Namgung HW, Kwon SY, et al. The pharmacokinetic profiles of oral doxofylline and factors influencing the serum level. Eur Res Cong Abstact Book 2007;Poster-2116: 350s
   Google Scholar
• Zhang XR, Chen XY, Hu LD, et al. Evaluation of in-vitro dissolution and in-vivo absorption for two different film-coated pellets of clarithromycin. Arch Pharm Res 2005;28:977-82
   PubMed Web of Science ®Google Scholar
• Huang HF, Lu Y, He HB, Tang X. Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. Drug Dev Ind Pharm 2008;34:676-82
   PubMed Web of Science ®Google Scholar
• Cipla therapeutic index, respiratory drugs, Zordox. CiplaDoc. Available from: http://www.cipladoc.com/therapeutic/admin.php?mode=prod&action=disp&id=650 [Last accessed 16 June 2009]
   Google Scholar
• Franzone JS, Cirillo R, Reboani MC. Pharmacological studies in animals of beta-hydroxyethyltheophylline, the major metabolite of doxofylline in humans. Methods Find Exp Clin Pharmacol 1991;13:289-99
   PubMedGoogle Scholar
• Bagnato GF. Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma. Eur Rev Med Pharmacol Sci 1999;3:255-60
   PubMedGoogle Scholar
• Dolcetti A, Osella D, De Filippis G, et al. Comparison of intravenously administered doxofylline and placebo for the treatment of severe acute airways obstruction. J Int Med Res 1988;16:264-9
   PubMedGoogle Scholar
• Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma – a double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit 2002;8:CR297-304
   PubMedGoogle Scholar
• Melillo G, Balzano G, Jodice F, et al. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial. Int J Clin Pharm Res 1989;9:397-405
   PubMedGoogle Scholar
• Poggi R, Brandolese R, Bernasconi M, et al. Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure. Chest 1989;96:772-8
   PubMedGoogle Scholar
• Cogo R, Castronuovo A. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis. Eur Rev Med Pharmacol Sci 2004;4:15-20
   Google Scholar
• Villani F, De Maria P, Ronchi E, Galimberti M. Oral doxophylline in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 1997;35:107-11
   PubMed Web of Science ®Google Scholar
• Cravanzola C, Reboani MC, Grosa G, Franzone JS. Doxofylline in rat brain in relation to locomotor activity. Drug Metab Dispos 1989;17:437-40
   PubMedGoogle Scholar
• Benditt DG, Benson DW, Kreitt J, et al. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias. Am J Cardiol 1983;52:1223-9
   PubMed Web of Science ®Google Scholar
• Cirillo R, Barone D, Franzone JS. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Arch Int Pharmacodyn 1988;295:221-37
   PubMedGoogle Scholar
• Dini FL. Chronotropic and arrhythmogenic effects of two methylxanthine bronchodilators, doxofylline and theophylline, evaluated by Holter monitoring. Curr Ther Res 1991;49:978-84
   Google Scholar
• Cipri A, Pozzar F, Dini FL. Heart rhythm changes in patients with chronic obstructive bronchopneumopathies: effects of different methylxanthine drugs. Minerva Cardioangiol 1992;40:31-9
   PubMedGoogle Scholar
• Giorgi M, Sestini P, Bracciale PM, et al. Treatment with xanthine derivative, doxofylline, in patients intolerant to theophylline. Eur Respir J 1993;6(Suppl 17): Abstract 417
   Google Scholar
• Evoniuk G, Jacobson KA, Shamin MT. α1- and α2-selective adenosine antagonists: in vivo characterization of cardiovascular effects. J Pharmacol Exp Ther 1987;242:882-7
   PubMed Web of Science ®Google Scholar
• Sacco C, Braghiroli A, Grossi E, Donner CF. The effects of doxofylline versus theophylline on sleep architecture in COPD patients. Monaldi Arch Chest Dis 1995;50:98-103
   PubMedGoogle Scholar
• Lazzaroni M, Gross E, Porro GB. The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients. Aliment Pharmacol Ther 1990;4:643-9
   PubMedGoogle Scholar
• Information, side effects and warnings of doxofylline methylxanthines. Medical, drugs, pharmaceuticals and diseases information. Available from: http://www.wordpress.rudramani.com/information-side-effects-and-warnings-of-doxofylline-methylxanthines/ [Last accessed 16 June 2009]
   Google Scholar
• Bagnato G, Fodale P, Bottari M. Clinical evaluation of doxofylline sachets in a pediatric population. Riv Eur Sci Med Farmacol 1989;11:359-63
   PubMedGoogle Scholar
• Cazzola M, Bettoncelli G, Sessa E, Cricelli C. Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med 2009;103:582-8
   PubMed Web of Science ®Google Scholar
• Piaz VD, Giovannoni MP. Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 2000;35:463-80
   PubMed Web of Science ®Google Scholar